# PATENTS & PROPRIETARY RIGHTS POLICY v2.2  
**Last updated:** 2025-05-10  

---

## 0. Purpose & Scope  
This notice secures all **PhantomInterface Collective (PIC)** dental-regeneration innovationsâ€”including the **Nine-Gate Regenerative Protocol v2.0**â€”through a layered IP strategy combining:

- Defensive publication  
- Trade-secret protection  
- Copyright  
- Patent strategy  
- Unfair-competition law  

> **Future Versions Clause:**  
> This policy applies to all **current and future versions** of the protocol, including updates, iterations, or improvements. Any subsequent versions will be covered under the same legal framework unless explicitly revised.

**Any commercial use requires a separate, written licence from PIC.**

---

## 1. Defensive Publication & Prior Art  
These disclosures establish **absolute prior art** under **35 U.S.C. Â§ 102(b), Art 54 EPC**, and equivalent statutes worldwide. Any later patent covering identical or obvious variants is **presumptively invalid**.

| Disclosure Channel      | Timestamp  | Persistent ID                                                             |
|-------------------------|------------|---------------------------------------------------------------------------|
| GitHub Repository       | 2025-04-23 | [github.com/phantominterface/teeth-that-will-not-fail](https://github.com/phantominterface/teeth-that-will-not-fail) |
| YouTube Timestamp Demo  | 2025-04-23 | [youtu.be/SaER7-QNF-k](https://youtu.be/SaER7-QNF-k)                        |
| Zenodo Archive          | 2025-05-04 | [DOI 10.5281/zenodo.15336594](https://doi.org/10.5281/zenodo.15336594)       |

> **Note:** All disclosures now include **v2.0 features** (endocrine regulation, microbiome stabilization, merged neuro-vascular gate, upgraded digital twin sensors).

---

## 2. Trade-Secret Portfolio (Confidential)  
Until formal patent filings are lodged, PIC treats the following elements as **trade secrets** under **Swiss UCA Art 162** and **EU Directive 2016/943**. Unauthorized reverse-engineering, disclosure, or patent filings covering these mechanisms is strictly prohibited:

| Code-Name         | Confidential Mechanism / Rationale                                                                 |
|-------------------|---------------------------------------------------------------------------------------------------|
| **CR-SOC Loop**     | Real-time biosensor lattice enforcing **K â‰ˆ 1** criticality to stabilize regenerative dynamics (Phase III).   |
| **C9-VASC-Guard**   | Inducible caspase-9 switch in engineered endothelial progenitors to **abort malignant angiogenesis**.       |
| **C7-ANABO-PRIME**  | HDAC-i micro-pulse + endocrine modulation (PTH + dCas9-TET1) for **epigenetic anabolic priming**.               |
| **C8-BIO-RECODE**   | Synbiotic rinse (Bifidobacterium/Prevotella + arginine/glycine buffer) for **oral biofilm re-programming**.    |

**By accessing this repository you agree not to:**  
1. Reverse-engineer or de-compile these mechanisms for commercial gain.  
2. Disclose technical details without PICâ€™s written consent.  
3. File patent applications covering substantially similar technology.

_Breaching this section triggers liquidated damages per LICENSE.md Â§ 6 (â‚¬250 000 intentional / â‚¬50 000 negligent) plus injunctive relief._

---

## 3. Copyright & Licence  
All text, code, diagrams, CAD assets, and protocol definitions (including v2.0) are Â© 2025 PhantomInterface Collective and released under the **PhantomInterface Non-Commercial Attribution Licence v2.1**.

- **Commercial or military use is prohibited** without a separate agreement.  
- **Attribution** is mandatory for any non-commercial derivative works.  

See **LICENSE.md** for full terms.

---

## 4. Patent-Filing Strategy & No-Challenge Clause  
PIC reserves the right to pursue **offensive or defensive patent protection** for any element of this technologyâ€”including all **v2.0 innovations**â€”at its discretion.

> **No-Challenge Clause:**  
> Contributors and downstream users agree not to **challenge** (or assist any third party in challenging) the validity or enforceability of any current or future PIC patent related to this project (see **CLA.md Â§ 2**).

---

## 5. Enforcement & Remedies  

| Violation                           | Primary Remedy                                    | Statutory Basis                          |
|-------------------------------------|---------------------------------------------------|------------------------------------------|
| Trade-secret misappropriation       | Injunction + compensatory & punitive damages      | Swiss SCC Art 273; EU Dir 2016/943       |
| Patented-method infringement        | Injunction + disgorgement + damages               | Swiss PatA Art 66; EPC Art 64            |
| Unauthorized commercial use         | Liquidated damages (â‚¬250 k / â‚¬50 k) + account takedown | LICENSE.md Â§ 6; DMCA Â§ 512            |
| Patent or IP challenge by contributor | Automatic CLA breach + injunctive relief         | CLA.md Â§ 2                               |

_Prevailing party is entitled to attorneysâ€™ fees and expert costs._

---

## 6. Jurisdiction & Venue  
All disputes are governed by **substantive Swiss law** and adjudicated exclusively in the **ZÃ¼rich Commercial Court (first instance)** per **JURISDICTION.md**.

---

## 7. Export-Control Warning  
Export or re-export of these technologies may require authorization under **Swiss/EU dual-use regulations** (e.g., EC Reg 2021/821). See **EXPORT_CONTROL.md**.

---

**Contact:**  
For commercial licensing or legal queries, contact ðŸ“§ societyaccelerationist2127299@proton.me (PGP available).  
